Illumina falls despite an earnings beat as research demand stays weak
Earnings results
- EPS beat +5.9%
$1.44 vs $1.36 expected, adjusted and excluding tariff refunds; GAAP $1.43
- Revenue beat +1.4%
$1.166B excluding tariff refunds vs $1.15B expected; reported revenue $1.129B
- Guidance
Raised full-year adjusted EPS excluding tariff refunds to $5.40–$5.45 from $5.30–$5.40
Earnings and the stock move
The earnings beat and higher profit forecast sit alongside an uneven demand picture. Clinical sequencing remains strong, but research and applied-market supply sales declined, while the underlying growth target outside China was unchanged. That makes the conversion of new NovaSeq X placements into recurring testing-supply sales the next useful signal. Tariff-refund accounting also separates reported sales from the figure used for guidance and consensus comparisons; it should not be mistaken for a demand shortfall.
Q3 2026 ended September 27 earnings recap
Illumina fell 17.4% during trading on October 30, 2026 despite an earnings beat and a higher profit forecast. Weak research demand remains a challenge for growth.
- Adjusted EPS, or profit per share, was $1.44 excluding tariff refunds, above $1.36 expected. GAAP EPS was $1.43.
- Reported revenue was $1.13 billion. Excluding expected tariff refunds credited to customers, revenue was $1.17 billion versus $1.15 billion expected; those credits reduced reported sales by $37 million.
- Clinical sequencing supply sales grew 14%, while research and applied-market sales fell 6%, excluding China, currency and acquisitions. Strength in medical testing is still offset by weaker research spending.
- Illumina placed more than 80 NovaSeq X sequencing instruments in the quarter. A larger installed base can create repeat demand for testing supplies as customers run more samples.
- The company raised full-year adjusted EPS guidance excluding tariff refunds to $5.4–$5.45 from $5.3–$5.4. Revenue guidance on the same basis rose to $4.64–$4.66 billion from $4.6–$4.64 billion.
- The target for underlying revenue growth outside China stayed above 5%, unchanged from the previous forecast. The higher headline forecast therefore comes without a higher target on that underlying measure.
Watch whether new instruments translate into stronger supply sales and research spending recovers. China market access and customer budgets remain risks; the charts end at the October 29 close, before earnings.
Financials and technicals
Charts through Oct 29, 2026. The session move above may reflect later news.
Technical setup and risks
The completed October 29 charts precede earnings. After the large decline, the former $257–$264 low area is overhead, not established current support. Regaining that range would begin repairing the gap; remaining below it leaves the prior trading range overhead. A new range needs time to develop.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.